BioCentury
ARTICLE | Clinical News

Amicus reports function outcomes data from Phase I/II of Pompe's disease candidate

October 6, 2017 5:56 PM UTC

Amicus Therapeutics Inc. (NASDAQ:FOLD) reported functional outcomes data from the Phase I/II ATB200-02 Study showing that IV ATB200/AT2221 improved muscle and pulmonary function in patients with Pompe's disease. Amicus CEO John Crowley told BioCentury the company expects to begin a Phase III trial sometime next year, but that Amicus is also working with regulators to "find the fastest path available to bring this medicine to patients."

The open-label, international trial enrolled 20 patients across 3 cohorts: ambulatory enzyme replacement therapy (ERT)-switch patients; non-ambulatory ERT-switch patients; and ERT-naïve patients...

BCIQ Company Profiles

Amicus Therapeutics Inc.

BCIQ Target Profiles

Acid alpha glucosidase (GAA)